Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018
| Autor: | Silvia Ulrich, Tobias J. Lange, S Holt, Michael Halank, Werner Seeger, Jürgen Behr, Dirk Skowasch, Frank Reichenberger, Martin Claussen, Matthias Held, Philipp Douschan, Heinrike Wilkens, Horst Olschewski, Stephan Krüger, Marius M. Hoeper, Hans Klose, H Bremer |
|---|---|
| Přispěvatelé: | University of Zurich, Olschewski, Horst |
| Rok vydání: | 2018 |
| Předmět: |
Lung Diseases
medicine.medical_specialty Consensus Development Conferences as Topic Hypertension Pulmonary 610 Medicine & health 030204 cardiovascular system & hematology 2705 Cardiology and Cardiovascular Medicine 03 medical and health sciences 0302 clinical medicine Quality of life Germany medicine Humans Intensive care medicine Lung business.industry Consensus conference medicine.disease Pulmonary hypertension Paediatric cardiology Respiratory Medicine medicine.anatomical_structure 030228 respiratory system Lung disease Practice Guidelines as Topic 10178 Clinic for Pneumology Cardiology and Cardiovascular Medicine business Medical ethics |
| Zdroj: | International Journal of Cardiology. 272:63-68 |
| ISSN: | 0167-5273 |
| Popis: | The 2015 European Guidelines on Pulmonary Hypertension did not only cover pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) associated with chronic lung disease. The European Guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase‑5 inhibitors, sGC stimulators) have not been sufficiently investigated in other forms of PH. Therefore, the European Guidelines do not recommend the use of these drugs in patients with chronic lung disease and PH. This recommendation, however, is not always in agreement with medical ethics as physicians sometimes feel inclined to treat other forms of PH which may affect quality of life and survival of these patients in a similar manner. To this end, it is crucial to consider the severity of both PH and the underlying lung disease. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Paediatric Cardiology (DGPK) was held in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were created, one of which was dedicated to the diagnosis and treatment of PH in patients with chronic lung disease. The 2018 updated recommendations of this working group are summarized in the present paper. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect